Skip to Accessibility Tools Skip to Content Skip to Footer

Positive phase 2 results reported for erenumab in the treatment of chronic migraine

Amgen announced that the company’s experimental drug, erenumab, has met the midstage goal of a placebo-controlled, Phase II study by reducing the number of migraine attacks per month in people with chronic migraine.

Erenumab, also known as AMG 334, is a fully human monoclonal antibody that targets the Calcitonin-Gene-Related-Petitide (CGRP) receptor.

The study was conducted over 12 weeks with 667 patients who experienced approximately 18 migraine days each month.

Patients receiving 70mg or 140mg doses via subcutaneous injection once a month experienced a reduction of 6.6 migraine days per month compared to a reduction of 4.2 migraine days in those receiving placebo. The results were found to be statistically significant.

The most common side effects were were pain at the injection site, upper respiratory tract infection, and nausea. No side effects were reported in more than 5% of patients receiving erenumab.

Additional data from the study are expected to be released later this year. 1-3

  1. Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine. June 8, 2016. Available at: http://www.amgen.com/media/news-releases/2016/06/amgen-announces-erenumab-amg-334-significantly-reduces-patients-monthly-migraine-days-in-phase-2-study-for-the-prevention-of-chronic-migraine/
  2. Amgen reports positive results for migraine drug erenumab. The Pharma Letter. June 10, 2016. http://www.thepharmaletter.com/article/amgen-reports-positive-results-for-migraine-drug-erenumab
  3. Wang, Christine. Amgen releases positive data for chronic-migraine prevention drug. CNBC. June 10, 2016. Available at: http://www.cnbc.com/2016/06/08/amgen-releases-positive-data-for-chronic-migraine-prevention-drug.html

Comments

  • jviper36
    3 years ago

    I am currently in the study for AMG334. The drug has worked beyond my expectations. I went from 10 migraines a month to one migraine a month. The study is coming to an end for me and believe me I wish I could stay on this medication indefinitely. It has made a positive impact on my life.

  • Guineverre
    3 years ago

    I am currently in a CGRP study, being run by a different pharmaceutical company. Unfortunately, it hasn’t helped me. I’ll find out in October whether I received the actual medication or a placebo. Im hoping I got the placebo so that I can try the real medication and maybe it will help me.

  • Luna
    3 years ago

    “The most common side effects were were pain at the injection site, upper respiratory tract infection, and nausea. No side effects were reported in more than 5% of patients receiving erenumab.”

    Wonder what the rest of the side effects are? And almost 95% reported side effects. Not too thrilling but maybe it will be just what some people need even though ” a reduction of 6.6 migraine days per month compared to a reduction of 4.2 migraine days in those receiving placebo”. Hey give me the placebo thanks. lol

  • Poll